ES2187518T3 - 3-(aminoalquilamino)-1-2-benzisoxazoles sustituidos y compuestos relacionados. - Google Patents

3-(aminoalquilamino)-1-2-benzisoxazoles sustituidos y compuestos relacionados.

Info

Publication number
ES2187518T3
ES2187518T3 ES94902374T ES94902374T ES2187518T3 ES 2187518 T3 ES2187518 T3 ES 2187518T3 ES 94902374 T ES94902374 T ES 94902374T ES 94902374 T ES94902374 T ES 94902374T ES 2187518 T3 ES2187518 T3 ES 2187518T3
Authority
ES
Spain
Prior art keywords
compounds
benzisoxazols
aminoalquilamino
substituted
related compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94902374T
Other languages
English (en)
Inventor
Mark G Palermo
Gerard J O'malley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Aventis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/150,301 external-priority patent/US5494908A/en
Application filed by Aventis Pharmaceuticals Inc filed Critical Aventis Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2187518T3 publication Critical patent/ES2187518T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

ESTA APLICACION SE REFIERE A COMPUESTOS DE LA FORMULA (I) EN DONDE R1, X, Y Y N SON COMO SE DEFINE EN LA ESPECIFICACION; Y A SALES DE ADICION DEL MISMO ACEPTABLES FARMACEUTICAMENTE Y A MEZCLAS DE ISOMEROS OPTICOS, GEOMETRICOS O RACEMICOS DEL MISMO; CUYOS COMPUESTOS SON UTILES PARA EL TRATAMIENTO DE VARIAS DISFUNCIONES DE LA MEMORIA CARACTERIZADAS POR UNA DISMINUCION DE LA FUNCION COLINERGICA TALES COMO LA ENFERMEDAD DE ALZHEIMER. LOS COMPUESTOS DE ESTE INVENTO TAMBIEN INHIBEN LA OXIDASA MONOAMINA Y POR LO TANTO SON UTILES COMO ANTIDEPRESIVOS.
ES94902374T 1992-11-23 1993-11-22 3-(aminoalquilamino)-1-2-benzisoxazoles sustituidos y compuestos relacionados. Expired - Lifetime ES2187518T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98002192A 1992-11-23 1992-11-23
US08/150,301 US5494908A (en) 1992-11-23 1993-11-12 Substituted 3-(aminoalkylamino)-1,2-benzisoxazoles and related compounds

Publications (1)

Publication Number Publication Date
ES2187518T3 true ES2187518T3 (es) 2003-06-16

Family

ID=26847521

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94902374T Expired - Lifetime ES2187518T3 (es) 1992-11-23 1993-11-22 3-(aminoalquilamino)-1-2-benzisoxazoles sustituidos y compuestos relacionados.

Country Status (14)

Country Link
US (2) US5580982A (es)
EP (1) EP0669920B1 (es)
JP (1) JP3462501B2 (es)
AT (1) ATE232529T1 (es)
AU (1) AU690529B2 (es)
CA (1) CA2149918A1 (es)
DE (1) DE69332691T2 (es)
DK (1) DK0669920T3 (es)
ES (1) ES2187518T3 (es)
FI (1) FI952481A (es)
MX (1) MX9307332A (es)
NO (1) NO304980B1 (es)
NZ (1) NZ258747A (es)
PT (1) PT669920E (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5494908A (en) * 1992-11-23 1996-02-27 Hoechst-Roussel Pharmaceutical Incorporated Substituted 3-(aminoalkylamino)-1,2-benzisoxazoles and related compounds
AU5919001A (en) * 2000-04-28 2001-11-12 Acadia Pharm Inc Muscarinic agonists
DK1828182T3 (da) * 2004-11-29 2010-05-10 Warner Lambert Co Terapeutiske pyrazol[3,4-B]pyridiner og indazoler
DE102005038947A1 (de) * 2005-05-18 2006-11-30 Grünenthal GmbH Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln
KR20120123089A (ko) * 2010-02-16 2012-11-07 화이자 인코포레이티드 5-ＨＴ₄ 수용체의 부분 효능제인 (Ｒ)-4-((4-((4-(테트라히드로푸란-3-일옥시)벤조［ｄ］이속사졸-3-일옥시)메틸)피페리딘-1-일)메틸)테트라히드로-2Ｈ-피란-4-올
KR20140091022A (ko) 2011-10-31 2014-07-18 제논 파마슈티칼스 인크. 벤젠술폰아미드 화합물 및 치료제로서의 그의 용도
CN104093716B (zh) 2011-10-31 2017-06-23 克赛农制药股份有限公司 联芳醚磺酰胺化合物及其作为治疗剂的用途
EA026393B1 (ru) 2012-05-22 2017-04-28 Дженентек, Инк. N-замещенные бензамиды и их применение в лечении боли
WO2014008458A2 (en) 2012-07-06 2014-01-09 Genentech, Inc. N-substituted benzamides and methods of use thereof
BR112015022488A2 (pt) 2013-03-14 2017-07-18 Genentech Inc triazolopiridinas substituídas e métodos de uso das mesmas
CN105492430B (zh) * 2013-03-15 2017-10-10 基因泰克公司 取代的苯并噁唑及其使用方法
EP2970156B1 (en) 2013-03-15 2018-07-25 Genentech, Inc. Substituted benzoxazoles and methods of use thereof
EA201691085A1 (ru) 2013-11-27 2017-02-28 Дженентек, Инк. Замещенные бензамиды и способы их применения
CN106715418A (zh) 2014-07-07 2017-05-24 基因泰克公司 治疗化合物及其使用方法
CA2986045A1 (en) 2015-05-22 2016-12-01 Genentech, Inc. Substituted benzamides and methods of use thereof
CN108137477A (zh) 2015-08-27 2018-06-08 基因泰克公司 治疗化合物及其使用方法
SG10202007787RA (en) 2015-09-28 2020-09-29 Genentech Inc Therapeutic compounds and methods of use thereof
MA43304A (fr) 2015-11-25 2018-10-03 Genentech Inc Benzamides substitués utiles en tant que bloqueurs de canaux sodiques
EP3854782A1 (en) 2016-03-30 2021-07-28 Genentech, Inc. Substituted benzamides and methods of use thereof
KR20190078587A (ko) 2016-10-17 2019-07-04 제넨테크, 인크. 치료 화합물 및 그의 사용 방법
JP2020511511A (ja) 2017-03-24 2020-04-16 ジェネンテック， インコーポレイテッド ナトリウムチャネル阻害剤としての４−ピペリジン−ｎ−（ピリミジン−４−イル）クロマン−７−スルホンアミド誘導体
WO2019165290A1 (en) 2018-02-26 2019-08-29 Genentech, Inc. Pyridine-sulfonamide compounds and their use against pain and related conditions
CN111936494A (zh) 2018-03-30 2020-11-13 豪夫迈·罗氏有限公司 作为钠通道抑制剂的取代的氢-吡啶并-吖嗪
ES2968678T3 (es) * 2018-04-27 2024-05-13 Univ Osaka Inhibidores del canal TRPC3 o TRPC6
WO2021079962A1 (ja) * 2019-10-24 2021-04-29 国立大学法人大阪大学 難聴の予防および／または治療用医薬組成物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3381617D1 (de) * 1982-03-17 1990-07-05 Asahi Chemical Ind Indazol-derivate.
US4590196A (en) * 1984-08-23 1986-05-20 Bristol-Myers Company Analgesic 1,2-benzisothiazol-3-ylpiperazine derivatives
EP0302423A3 (en) * 1987-08-07 1991-01-09 Hoechst-Roussel Pharmaceuticals Incorporated 1-phenyl-3-(1-piperazinyl)-1h-indazoles, a process and intermediates for their preparation, and the use thereof as medicaments
US5134236A (en) * 1987-08-07 1992-07-28 Hoechst-Roussel Pharmaceuticals Incorporated Phenylhydrazones as intermediates 1-phenyl-3-(1-piperazenyl)-1H-indazoles
US4999356A (en) * 1987-08-07 1991-03-12 Hoechst-Roussel Pharmaceuticals, Inc. 1-phenyl-3-(1-piperazinyl)-1H-indazoles
US5364866A (en) * 1989-05-19 1994-11-15 Hoechst-Roussel Pharmaceuticals, Inc. Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics
US4954503A (en) * 1989-09-11 1990-09-04 Hoechst-Roussel Pharmaceuticals, Inc. 3-(1-substituted-4-piperazinyl)-1H-indazoles
FR2654104B1 (fr) * 1989-11-07 1992-01-03 Adir Nouveaux derives du 1,2-benzisoxazole, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
US5147881A (en) * 1990-11-14 1992-09-15 Pfizer Inc 4-(1,2-benzisoxazolyl)piperidine antipsychotic agents
UA45944C2 (uk) * 1991-03-28 2002-05-15 Ейсай Ко., Лтд Гетероцикло-циклічні похідні амінів або їх фармацевтично прийнятні солі, проміжні сполуки, фармацевтична композиція, спосіб інгібування холінестерази, спосіб одержання гетероцикло-циклічних похідних амінів

Also Published As

Publication number Publication date
NZ258747A (en) 1997-02-24
EP0669920B1 (en) 2003-02-12
AU5676594A (en) 1994-06-22
PT669920E (pt) 2003-06-30
EP0669920A1 (en) 1995-09-06
US5580982A (en) 1996-12-03
JP3462501B2 (ja) 2003-11-05
FI952481A0 (fi) 1995-05-22
US6046203A (en) 2000-04-04
MX9307332A (es) 1994-07-29
ATE232529T1 (de) 2003-02-15
NO952018D0 (no) 1995-05-22
DK0669920T3 (da) 2003-05-26
DE69332691D1 (de) 2003-03-20
EP0669920A4 (en) 1995-10-25
DE69332691T2 (de) 2003-12-18
JPH08506094A (ja) 1996-07-02
FI952481A (fi) 1995-05-22
CA2149918A1 (en) 1994-06-09
AU690529B2 (en) 1998-04-30
NO304980B1 (no) 1999-03-15
NO952018L (no) 1995-05-22

Similar Documents

Publication Publication Date Title
ES2187518T3 (es) 3-(aminoalquilamino)-1-2-benzisoxazoles sustituidos y compuestos relacionados.
ES2166379T3 (es) 2-aminotetralinas sustituidas.
CO4930259A1 (es) Derivados 6,6-heterobiciclicos sustituidos y composiciones farmaceuticas que los contienen
ES2154262T3 (es) Uso de compuestos macrolidos para enfermedades oculares.
PA8442001A1 (es) Derivados de pirimidina biciclica condensada
CR6165A (es) Procedimientos e intermedios para preparar compuestos anticancerosos
GT200000005A (es) Derivados biciclicos sustituidos utiles como agentes contra el cancer.
GT199900140A (es) Derivados de quinolin-2-ona alquinilsustituidos utiles como agentes anticancerosos.
PA8544901A1 (es) Derivados de oxazol
ECSP056192A (es) 3-fluoro-piperidinas como antagonistas de nmda/nr2b
ES2181766T3 (es) Analogos de delda 12,13-isotaxol, uso antineoplasico y composiciones farmaceuticas que los contienen.
SE9702564D0 (sv) New compounds
AR028624A1 (es) Heterociclilalquilaminas como antagonistas de receptores muscarinicos
DE69229339D1 (de) Kristallines tiagabinehydrochlorid-monohydrat, seine herstellung und verwendung
ES2067874T3 (es) Derivados de acetamida.
MX9100607A (es) Compuesto triciclico novedoso o sales del mismo,metodo para producir el mismo y agente antimicrobiano que lo contiene
ES2119046T3 (es) Compuestos dihalopropenos, insecticidas/acaricidas que los contienen como agentes activos y compuestos intermediarios para uso en su produccion.
ATE242220T1 (de) Benzimidazolderivate mit dopaminerger wirkung
ES2129005B1 (es) Composicion para el tratamiento de semillas de arroz.
AR004474A1 (es) Compuestos de 10-aminoalifatil-dibenz [b,f]oxepinas antineurodegenerativamente activas, utiles para el tratamiento de estados neurodegenerativos y composiciones farmaceuticas que los contienen
DE50204884D1 (de) Kosmetische formulierung enthaltend dihydroxyaceton
ATE196464T1 (de) Benzol-derivate, verwendbar für ischämische erkrankungen
GT199900083A (es) Combinaciones terapeuticas para la fragilidad musculoesqueletica.
UY26329A1 (es) Antagonistas de los receptores de vitronectina
AR003471A1 (es) Metodo de tratamiento de las convulsiones en un paciente que lo necesite con compuesto n-(pirrol-1-il)piridinaminas no substituidos y substituidas,composicion farmaceutica y uso de dichos compuestos en la preparacion de una composicion farmaceutica para el tratamiento de las convulsiones.